ERBB2 and breast carcinoma: Two weeks after completion of doxorubicin treatment, the changes in several altered plasma metabolomes were found to be correlated with the changes in at least one of the altered cardiac parameters, both in HER2-positive and HER2-negative breast cancer patients.